	US 12,214,012 B2
	Combined preparations for the treatment of cancer
Frederic Triebel, Versailles (FR)
Assigned to IMMUTEP S.A.S., Saint-Aubin (FR)
Filed by IMMUTEP S.A.S., Orsay (FR)
Filed on Jul. 1, 2020, as Appl. No. 16/918,527.
Application 16/918,527 is a continuation of application No. 15/105,789, granted, now 10,736,940, previously published as PCT/EP2014/078779, filed on Dec. 19, 2014.
Claims priority of application No. 1322626 (GB), filed on Dec. 19, 2013.
Prior Publication US 2020/0323957 A1, Oct. 15, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 31/282 (2006.01); A61K 31/4745 (2006.01); A61K 31/555 (2006.01); A61K 45/06 (2006.01); C07K 14/705 (2006.01)

CPC A61K 38/1774 (2013.01) [A61K 31/282 (2013.01); A61K 31/4745 (2013.01); A61K 31/555 (2013.01); A61K 45/06 (2013.01); C07K 14/70503 (2013.01); C07K 2319/30 (2013.01)]

12 Claims

1. A method of treating or ameliorating a cancer, which comprises:

administering to a subject in need of such treatment or amelioration an effective amount of:

a derivative of LAG-3 protein that is able to bind to MHC class II molecules, wherein the derivative comprises domains D1 and D2 of human LAG-3 protein, and wherein the derivative is fused to an Immunoglobulin Fc sequence; and

an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor; and

synergistically reducing tumor growth in the subject, the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.